News Cytokinetics, Incorporated

Stocks

CYTK

US23282W6057

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 13/07/2026 BST			5-day change	1st Jan Change
82.24 ^USD	-3.10%		-3.89%	+29.43%

07-07	RBC Capital Adjusts Cytokinetics Price Target to $117 From $119, Maintains Outperform Rating	MT
07-02	Cytokinetics Insider Sold Shares Worth $1,287,000, According to a Recent SEC Filing	MT

All News

Mentions Relevance

07-07	RBC Capital Adjusts Cytokinetics Price Target to $117 From $119, Maintains Outperform Rating	MT
07-07	Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026	AQ
07-02	Cytokinetics Insider Sold Shares Worth $1,287,000, According to a Recent SEC Filing	MT
06-29	Cytokinetics Insider Sold Shares Worth $266,390, According to a Recent SEC Filing	MT
06-29	Cytokinetics Seen Gaining From Myqorzo Momentum to Treat Heart Conditions, UBS Says	MT
06-29	UBS Upgrades Cytokinetics to Buy From Neutral, Adjusts Price Target to $115 From $69	MT
06-21	Certain Options of Cytokinetics, Incorporated are subject to a Lock-Up Agreement Ending on 21-JUN-2026.	CI
06-21	Certain Common Shares of Cytokinetics, Incorporated are subject to a Lock-Up Agreement Ending on 21-JUN-2026.	CI
06-17	Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
06-09	Cytokinetics, Incorporated Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 09:18 AM
06-08	Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program	AQ
06-02	Cytokinetics Insider Sold Shares Worth $1,111,200, According to a Recent SEC Filing	MT
06-01	Cytokinetics announces launch of Myqorzo (aficamten) in Germany for symptomatic obstructive hypertrophic cardiomyopathy	RE
06-01	Cytokinetics launches Myqorzo® (aficamten) in European Union, with first commercial availability in Germany	RE
06-01	Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany	GL
06-01	Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany	AQ
06-01	Cytokinetics Launches Myqorzo in European Union with First Commercial Availability in Germany	CI
05-28	Cytokinetics Insider Sold Shares Worth $579,075, According to a Recent SEC Filing	MT
05-27	Cytokinetics to Participate in June Investor Conferences	AQ
05-27	Cytokinetics, Incorporated - Shareholder/Analyst Call
05-20	Cytokinetics Insider Sold Shares Worth $264,915, According to a Recent SEC Filing	MT
05-20	Cytokinetics to Hold Annual Meeting of Stockholders	AQ
05-18	Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	AQ
05-14	Cytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB)	AQ
05-12	Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference	AQ